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Mechanisms of Activity-dependent Plasticity in Cellular Nitric
Oxide-cGMP Signaling*□S
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Cellular responsiveness to nitric oxide (NO) is shaped by past
history of NO exposure. The mechanisms behind this plasticity
were explored using rat platelets in vitro, specifically to deter-
mine the relative contributions made by desensitization of NO
receptors, which couple to cGMP formation, and by phosphodi-
esterase-5 (PDE5), which is activated by cGMP and also hydro-
lyzes it. Repeated delivery of brief NO pulses (50 nM peak) at
1-min intervals resulted in a progressive loss of the associated
cGMP responses, which was the combined consequence of
receptor desensitization and PDE5 activation, with the former
dominating. Delivery of pulses of differing amplitude showed
that NO stimulated and desensitized receptors with similar
potency (EC50 10–20 nM). PDE5 activation was highly sensi-
tive toNO,with a single pulse peaking at 2 nM being sufficient to
evoke a 50% loss of response to a subsequent near-maximal NO
pulse. However, the activated state of the PDE subsided quickly
after removal of NO, the half-time for recovery being 25 s. In
contrast, receptor desensitization reverted much more slowly,
the half-time being 16 min. Accordingly, with long (20-min)
exposures, NO concentrations as low as 600 pM provoked signif-
icant desensitization. The results indicate that PDE5 activation
and receptor desensitization subserve distinct short term and
longer term roles asmediators of plasticity inNO-cGMP signal-
ing. A kinetic model explicitly describing the complex interplay
between NO concentration, cGMP synthesis, PDE5 activation,
and the resulting cGMP accumulation successfully simulated
the present and previous data.
Nitric oxide (NO) is an intercellular messenger molecule in
most tissues of the body and exerts physiological effects by
binding to receptors possessing intrinsic guanylyl cyclase (GC)4
activity. The receptor proteins are known by various names,
including the homogenate-based one, soluble guanylyl cyclase,
but here we simply call them NO receptors because this termi-
nology is conceptually more informative in a cellular context.
Synthesis of cGMP from GTP that follows receptor activation
can engage a number of downstream targets, including cGMP-
dependent protein kinase, to bring about alterations in cell
function, such as smooth muscle relaxation and neural trans-
mission (1–3).
In common with other hormone or transmitter signaling
pathways, the sensitivity of theNO-cGMPpathway is subject to
short term and long term regulation. Enduring exposure of cells
toNO (hours ormore) leads to a loss of NO responsiveness that
in the cardiovascular system contributes to the clinical prob-
lem of tolerance to nitrovasodilator therapy (4–6). One
mechanism here is a gradual loss of the NO receptor mRNA
and protein (7, 8). Conversely, a chronic lack of NO leads to
supersensitivity that has been attributed to increased NO
receptor activity (9, 10).
Short term regulatory mechanisms serve to shape acute cel-
lular cGMP responses to NO and may involve NO receptor
desensitization, reducing the rate of cGMP formation (11), acti-
vation of phosphodiesterases (PDEs) that consume cGMP (12),
or combinations of the two (13, 14). These short term mecha-
nisms may also be quite sustained. For example, relatively brief
(5 min) exposures of cells to NO can reduce responsiveness to
NOanhour later, a phenomenon that correlatedwith increased
activity of PDE5 (15). This PDE isoform, which is inhibited by
drugs like sildenafil (Viagra) used to treat erectile dysfunction,
contains a non-catalytic cGMP binding site whose occupation
stimulates catalytic activity (16, 17). Reciprocally, shortly after
removing the endothelial source of NO, blood vessels develop a
supersensitivity toNO-induced relaxation, aneffect thatwas spec-
ulated to reflect increased NO receptor responsiveness (18).
Addressing directly the relative contributions of NO recep-
tors and PDEs to the regulation of NO-cGMP signaling is prob-
lematic in complex tissues because it is very difficult tomeasure
their activities accurately. Rat platelets maintained in vitro, on
the other hand, have merit as an experimental model for these
purposes because they are physiological NO targets, homog-
enous, and are also extremely small (about 1 m in diameter),
minimizing problems of compartmentation of the signaling
proteins and of diffusion delays in access of applied agents to
the cell interior. In addition, they exist naturally in suspension,
which is ideal for kinetic studies, they have an abundance ofNO
receptors of just one type (11), and the only detectable PDE
that hydrolyzes NO-evoked cGMP signals is PDE5 (13). Expo-
sure of these cells to persistent NO generates only very tran-
sient cGMP responses, mostly terminating within 10 s of NO
application; this profile has been explained by a combination of
receptor desensitization and PDE5 enhancement (13). The
questions addressed here are whether or not these adaptations
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persist beyond the period of NO application to influence sub-
sequent cellular responsiveness and, if so, for how long, and
what are their relative contributions to the plasticity? Central to
the feasibility of obtaining answers was our recent development
of amethod for delivering repeatedNOpulses of known ampli-
tude and duration (14), allowing controlled conditioning NO
exposures to be followed by test exposures after selected time
intervals in NO-free solution.
EXPERIMENTAL PROCEDURES
Materials—Proline-NONOate, diethylenetriamine-NONO-
ate, spermine NONOate, and 2–4-carboxyphenyl-4,4,5,5,-tet-
ramethylimidazoline-1-oxyl-3-oxide (CPTIO) were obtained
from Axxora Ltd. (Nottingham, UK); sildenafil was supplied by
the Chemistry Division of theWolfson Institute for Biomedical
Research (London, UK). Other special chemicals were from
Sigma-Aldrich. The human embryonic kidney 293 cell line
expressing bovine 11-GC and human PDE5A1 (HEK-GC/
PDE5 cells (19)) and the phospho-PDE5 antibody were kindly
supplied by Professor Doris Koesling (Univ. of Bochum,
Germany).
Platelets—These were prepared from rat blood using meth-
ods described previously (13) and incubated at 37 °C in a solu-
tion containing 137 mMNaCl, 2.7 mM KCl, 0.5 mMMgCl2, 0.55
mMNaH2PO4, 25mMTris, 5.6mMD-glucose, 0.3mMurate, and
0.1 mM L-nitroarginine supplemented with superoxide dis-
mutase (1000 units/ml), pH 7.4. The platelets were maintained
at 0.5 mg of protein/ml or, for investigating PDE5 phosphoryl-
ation, at twice this concentration.
NO Delivery and cGMPMeasurement—Calibrated pulses of
NO were administered using a combination of a fast NO
releaser, proline-NONOate (half-life  1.8 s), and a slow NO-
consumer, CPTIO (50 M), as described in detail (14). As
before, calibration was carried out by directly measuring the
NO concentration attained by standard mixtures. Stock pro-
line-NONOate solutionswere then prepared to give the desired
final peak NO concentrations (which are proportional to the
donor concentration) when diluted 1:100 into the platelet sus-
pension containing CPTIO. The pulses illustrated in the figures
are simulations based on the kinetics of the reaction and closely
resemble the recorded NO profiles, except that the recorded
profiles are artificially slowed by the electrode response time
(14). Clamped NO concentrations were achieved with a mix-
ture of CPTIO (50 M) and one of the slower NO releasers,
spermine-NONOate (half-life 39min) or diethylenetriamine
NONOate (half-life 20 h), depending on the duration of the
experiment (20). Aliquots of platelets were inactivated in boil-
ing buffer, and the amounts of cGMP and protein were meas-
ured as before (14). In many of the experiments, rapid (2-s)
exposures to NO in the presence or absence of sildenafil were
made to measure the initial rate of cGMP accumulation as pre-
cisely as possible. Sampling was done by rapidly dispensing an
aliquot of platelets (50 l) preincubated with CPTIO onto a
0.5-l bead of NO donor (and a separate 0.5-l bead of silde-
nafil, when used) deposited immediately beforehand in the bot-
tom of a 1.5-ml Eppendorf tube prewarmed to 37 °C (time 0)
and then quickly withdrawing the aliquot back into the pipette
before inactivating it (time  2 s). Based on measurements
using 0.5-l beads of India ink, mixing was complete 72  10
ms (mean S.E.; n 5) after the initial addition of the platelets
(see supplemental Fig. S1). At the applied concentration (100
M), maximally effective concentrations of sildenafil are
expected intracellularly almost instantaneously; from the
molecular weight (494) and polar surface area (109 Å2), the
membrane permeability coefficient of sildenafil is expected to
be about 1.3  106 cm/s (21), which predicts an intracellular
concentration of 0.1M after 14ms in a platelet (assumed to be
a sphere of radius 0.5 m). The effect of 0.1 M sildenafil on
the early rise in cGMP would be indistinguishable from maxi-
mum PDE5 inhibition, as determined from the kinetics of inhi-
bition of PDE5 by sildenafil at steady state in rat platelets (13).
In each experiment there were 3–4 independent runs of each
condition; results are presented as the means  S.E. Except
where impractical, extracellular/bound cGMP sustained
through prior NO exposure was measured by inactivating an
aliquot of platelets immediately before re-exposure. In agree-
ment with prior detailed studies (13), the values ranged from 5
to 25 pmol/mg protein depending on conditions. Unless indi-
cated otherwise (Fig. 3), results are given after subtraction of
this pool of cGMP.
PDE5 Phosphorylation—After incubation and treatment, ali-
quots of platelets (0.1 ml) were inactivated with 25 l of a Lae-
mmli-type buffer, giving a final concentration of 62 mM Tris-
HCl, pH 6.8, 2% (w/v) SDS, 0.01% (w/v) bromphenol blue, 10%
(w/v) glycerol, and 5% (v/v) -mercaptoethanol. HEK-GC/
PDE5 cells were grown in 48-well plates and were then incu-
bated and exposed to S-nitrosoglutathione as described (19).
After treatment, the medium was aspirated and replaced with
the above Laemmli-type buffer. All samples were kept on ice
until the end of the experiment when they were frozen at
80 °C until needed. Electrophoresis was carried out in 4–15%
gradient SDS-PAGE gels (Bio-Rad). Gels were equilibrated for
30 min in transfer buffer (50 mM Tris base, 384 mM glycine, 5%
methanol) with the addition of 0.05% Triton X-100 and 1/1000
(v/v) antioxidant solution (2 M sodium bisulfite in 10% dimeth-
ylformamide). Proteins were transferred to hydrated polyvi-
nylidene difluoride membranes (Immun-Blot, Bio-Rad) in a
submerged blotting apparatus (TE22, Hoefer Inc., Holliston,
MA) using a current of 0.38 A for 90 min in transfer buffer plus
0.01%SDS, afterwhich the blotswere allowed to dry completely
at room temperature before being stored at 4 °C until required.
Blots were submerged in methanol for 10 s, equilibrated in
Tris-buffered saline for 5 min, and then blocked for 1 h in 3%
skimmed milk diluted in Tris-buffered saline with 0.2% Tween
20. Anti-phospho-PDE5 antibody was diluted 1/1000 into
blocking buffer for overnight incubation at 4 °C with agitation.
Blots were washed 3 times (5 min each) in Tris-buffered saline
containing 0.05% Tween 20. Secondary antibody conjugated to
horseradish peroxidase (goat anti-rabbit, Pierce) was applied at
10 ng/ml in blocking buffer for 2 h at room temperature with
agitation. After washing (as before), blots were developed in
chemiluminescence substrate (Supersignal West Pico, Pierce)
and exposed to Amersham Biosciences Hyperfilm ECL (GE
Healthcare). Images from autoradiographs were captured in
GeneSnap (Syngene, Cambridge, UK), and the relative intensity
of bands was quantified with GeneTools (Syngene).
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Vasodilator-stimulated Phosphoprotein (VASP) Phospho-
rylation—Phosphorylated VASP in platelets was detected by
immunoblotting as described previously (22).
Modeling—Equations encapsulating the scheme presented
under “Results” were solved in Mathcad 14 (Adept Scientific,
Letchworth, Herts, UK). The NO pulse input was as described
before (14). The results of the calculations were in molar units
(concentrations or rates), whichwere converted into the exper-
imental units (pmol/mg protein) by assuming 1mg of protein is
equivalent to 2.5 l (23).
RESULTS
Progressive Tachyphylaxis of NO-cGMP Signaling—In the
first experiment pulses of NO peaking at a concentration of 50
nM after 2 s and declining to 0 after 15–20 s were delivered at
1-min intervals. This pulse height gives near-maximal NO
receptor activation (14). The apparent GC activity was
recorded during each pulse by measuring cGMP accumulation
over a 2-s period in the presence of sildenafil in high enough
concentration (100 M) to effectively abolish PDE5 activity
(13). From a control activity of around 230 pmol/mg of pro-
tein/2 s, a single preceding NO pulse caused the activity to fall
by 45%. With succeeding pulses, further reductions occurred
until a steady 78% desensitization was reached after 5–6 pulses
(Fig. 1A).
To gauge concomitant alterations in PDE5 activity, cGMP
accumulation during the first 2 s of each pulse was measured in
the same experiments in the absence of sildenafil. To begin
with, the control responses were not much smaller than with
sildenafil present (180 pmol/mg of protein/2 s), signifying a low
initial activity of PDE5, but 1 min after the first NO pulse the
response was down to about a third of its initial amplitude.
Additional pulses elicited further reductions until, after 4–6
pulses, the response amplitude became relatively constant at
about 15 pmol/mg of protein/2 s, which was less than 10% that
of the starting value (Fig. 1A).
Conceivably, some of the fade taking place in the presence of
sildenafil under these conditions could be caused by the
appearance of PDE activity other than that of PDE5. To exam-
ine this possibility, PDE activity in the presence of sildenafil was
measured after the same sequence of pulses. This was carried
out by adding sildenafil just before the final (sixth) pulse and
then charting the decline in platelet cGMP levels once the NO
pulse had decayed. The outcome (Fig. 1C) showed a very slow
rate of loss of cGMP that was quantitatively the same as pre-
dicted from the measured kinetics of inhibition by sildenafil
under steady-state conditions in rat platelets (broken line, Fig.
1C). This result shows that there was no unsuspected PDE
activity and also attests to the expected very rapid penetration
of sildenafil into the platelets (see “Experimental Procedures”).
These findings demonstrate that brief periods of NO expo-
sure induce a progressive reduction of subsequent responsive-
ness (tachyphylaxis) and that the tachyphylaxis is caused by a
mixture of receptor desensitization and PDE5 activation, with
the former dominating under the conditions of this experi-
ment. Moreover, the alterations in both components must be
quite enduring; otherwise, summation with repeated pulses
would not have occurred.
FIGURE1.Progressive tachyphylaxisafter repeatedNOpulses.A, pulsesof
NO peaking at 50 nMwere delivered to platelets at 1-min intervals (simulated
at the top), and cGMPaccumulationover 2 swasmeasuredeachminute in the
presence and absence of sildenafil (100 M). Dashed lines are predictions of
themodel (Fig. 6 and Table 1) with GCmax 140M/s and Vp2 90M/s and
k3  1  10
7
M
1s1. The dotted line providing a better fit to the cellular
activity (open squares) is anextendedversionof that shown inFig. 6B, inwhich
the active, cGMP-bound form of PDE5 (cGMP-PDE5*) undergoes a transition
to a more stable (putatively phosphorylated) state, with forward and back-
ward rate constants of 2  103 and 6  104 s1, respectively. The latter
value was chosen to match the 20-min reported half-life of phosphorylated
PDE5 (19) and the former to fit the experimental data.B,model predictions for
the different states of the receptor accounting for the output seen inA. C, test
for the appearance of new PDE activity associated with tachyphylaxis. Plate-
lets given 6 pulses (as in A) have desensitized NO receptors, as indicated by
the reduction in cGMP generation during the first 2 s of the last pulse (filled
bars in the inset: control response (C), desensitized response (D)). In themain
panel, samples of platelets were subjected to the 6th pulse in the presence of
sildenafil (100M), and cGMPwasmeasured periodically over the next 3 min
to assess PDE activity. The dashed line is a fit to the model (Fig. 6 and Table 1)
assuming GCmax 140M/s and k3 0.53 10
7
M
1s1, giving the levels of
control and desensitized GC indicated by the open bars in the inset. The time-
course of the NO pulse is simulated for comparison (solid line).
Activity-dependent Plasticity in Cellular NO-cGMP Signaling
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Progress and NO Concentration Dependence of Receptor
Desensitization—The evolution of the desensitized state was
examined bymeasuring the apparent GC activity (2-s exposure
to a 50 nM pulse in the presence of sildenafil) at various times
after delivering a single NO pulse (50 nM peak amplitude).
Therewas an initial fall in apparentGCactivity, bottoming near
the end of theNOpulse (15–20 s), and then a partial recovery to
a steady desensitized level (Fig. 2A). A persistence of the desen-
sitized state for more than a minute explains the summation
observed in Fig. 1A.
The concentration-response curve for NO-induced desensi-
tization was examined by giving three identical pulses of NO (1
per min) of differing peak amplitude (0.1–100 nM) and, a
minute later, measuring the apparent GC activity (2-s expo-
sure) generated in response to a fixed 50 nM pulse. The results
showed that 50% desensitization was achieved with a pulse
height of about 20 nMNO (Fig. 2B). Measurement of the recep-
tor activation curve in the same experiment (in untreated plate-
lets) showed an EC50 of about 10 nM, in agreement with previ-
ous findings with this method (14) and with measurements
using clamped NO concentrations (13). Thus, acute receptor
activation and desensitization occur over similar NO concen-
tration ranges.
Progress and NO Concentration Dependence of PDE5 Activa-
tion in Comparison with Receptor Desensitization—Single NO
pulses of different amplitudes were administered, and at vary-
ing times afterward, the cGMP accumulation occurring over 2 s
in response to a fixed (50 nM) pulse was recorded in the pres-
ence and absence of sildenafil. The aim was to differentiate
changes in function of the receptor alone (test plus sildenafil)
and the receptor plus PDE5 (test minus sildenafil). The net
cellular response (comprising changes in receptor plus PDE5)
altered radically. After an NO pulse as low as 2 nM (peak), the
cellular response was depressed by 50% after 10 s but then
recovered, apparently completely, by 2min (Fig. 3A). NOpulses
of increased amplitude (5, 10, and 50 nM) gave greater initial
depressions whose amplitudes were graded with the NO pulse
height, the largest causing effectively complete inhibition of
cGMP accumulation 10–20 s afterward. In all cases, however,
the responses recovered at similar rates, reaching an apparent
steady-state value after about 2 min with a half-time of around
25 s. After the 50 nMNOpulse, the resulting steady-state ampli-
tude was clearly depressed relative to the control (no pre-expo-
sure toNO).When assayed in the presence of sildenafil, there
was little obvious change in the receptor output over the
whole time-course after pulses of 2–10 nM NO, but a 50 nM
pulse gave30%depression that lasted for the 10-min duration
of the experiment (Fig. 3B).
Recovery from Desensitization—The foregoing experiment
indicates that PDE5 activation makes a profound contribution
to short term tachyphylaxis, whereas receptor desensitization
becomes evident with larger pulses and has a longer-lasting
role. To find out how long desensitization persists, platelets
were given a sequence of 4NOpulses (50 nM peak; 1 permin) to
provoke tachyphylaxis, and then recovery was monitored over
the next hour by periodically testing the response (2 s) to a 50
nM NO pulse in the presence of sildenafil. Controls included
performing the test sampling in the absence of sildenafil (to
check for possible changes in PDE5 activity) and the running of
untreated samples alongside. The results showed that therewas
a slow but apparently complete recovery of receptor function,
the half-time being near 16 min (Fig. 4). With the exception of
the first test sample (assayed during the last of the conditioning
pulses), there was little effect of omitting sildenafil from the test
samples, consistent with PDE5 activity reverting quickly to its
very low resting level.
PDE5 Phosphorylation—The recovery of the PDE5 activity in
these experiments was unexpectedly rapid considering pre-
vious evidence from human platelets that activation of PDE5
can last much longer, being still evident 1 h after a 5-min
exposure to 1 M diethylamine NONOate (15). From studies
on model cell lines, the enduring activity has been attributed
to phosphorylation by cGMP-dependent protein kinase of a
serine residue on the PDE5 enzyme, resulting in a slowed
dissociation of cGMP from its agonist site (19). The much
faster reversal observed in the present experiments, there-
fore, suggests either that PDE5 does not become phospho-
FIGURE 2.Characteristics of NO receptor desensitization. A, platelets were
given a single NO pulse peaking at 50 nM (simulated by a solid line at the
bottom), and the apparent GC activity was monitored by measuring cGMP
accumulation in response to a second NO pulse (2-s exposure) delivered at
various times afterward in the presence of 100 M sildenafil. The first point is
a control 2-s exposure to the pulse in the presence of sildenafil. The broken
line is the model prediction (Fig. 6 and Table 1) assuming GCmax 138 M/s
and k3 0.7 10
7
M
1s1. B, plateletswere given threeNOpulses peaking at
different concentrations (abscissa) and, a minute after the last pulse, were
given a test pulse (50 nM amplitude) in the presence of 100M sildenafil. The
rise in cGMP over 2 s was normalized to the value from control (not NO-
pretreated) platelets (open symbols). In the same experiment the receptor
activation curve for NO was measured by exposing control platelets to the
same range of NO pulses for 2 s in the presence of sildenafil (filled symbols).
Broken lines aremodel predictions (Fig. 6 and Table 1) with GCmax 138M/s
and k3 0.7 10
7
M
1s1.
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rylated with the pulses of NO used here (amplitude up to 50
nM) or that phosphorylation reverses much more rapidly
than in human platelets.
Onmonitoring the level of PDE5 phosphorylation by immu-
noblotting (Fig. 5A), no significant alteration was detectable
during a 2-min period, after giving a 50 nMNOpulse. The same
result was obtained when NO was present throughout the
2-min period in a clamped concentration of 50 nM when, as
reported before (13), cGMP also rose only transiently (Fig. 5B).
In contrast, when faced with a clamped 50 nM NO concentra-
tion in the presence of sildenafil (100 M), cGMP rose to very
high levels which were maintained over 2 min (Fig. 5B), in
agreement with previous findings (13). Under these conditions,
a trend toward increased PDE5 phosphorylation with time was
evident in some runs (inset, Fig. 5A), but the mean levels were
not significantly different from controls (Fig. 5A). When many
more samples were analyzed, however, a 2-min exposure to 50
nM clamped NO in the presence of sildenafil generated a mod-
est but significant increase in PDE5 phosphorylation (145 
17% of control; n 13; p 0.0027 by paired t test). As a positive
control for the phospho-PDE5 antibody, HEK cells expressing
NO-activatedGC and PDE5were challengedwith 100M S-ni-
trosoglutathione for 5 or 10 min; mean increases of up to 700%
of basal levels were observed (Fig. 5A), consistent with a prior
publication using the same cells and methodology (19).
The possibility then arose that the concentration of NO to
which the platelets were exposed in the above experiments (50
nM) was too high, particularly in view of evidence that the con-
FIGURE 3. Differential rates of recovery of PDE5 activity and receptor desensitization. Platelets were exposed to single NO pulses of varying amplitude
(simulated in the inset at the top), and cGMP responses (2 s) to near-maximal test NO pulse (50 nM) in the absence (A) and presence (B) of sildenafil were then
chartedover time in comparisonwith the amplitudeof control responses to the same test pulse, shownat time 0. Because of the complexity of this experiment,
it was not practicable tomeasure (and correct for) extracellular/bound cGMP resulting from prior NO exposure. The predictions of themodel (Fig. 6 and Table
1) for the experiment are shown in C and Dwith GCmax 127 M/s, Vp2 75 M/s, and k3 1 10
7
M
1s1.
FIGURE 4. Recovery from receptor desensitization. Platelets were given 4
NO pulses (50 nM peak, 1 per min), and subsequent responsiveness were
testedperiodically over thenext hour by exposing them to a further 50nMNO
pulse for 2 s in the absence (open symbols) or presence (filled symbols) of
sildenafil (100 M). The first points in the time-course represent the values
measured during the last of the conditioning NO pulses. Values are normal-
ized to control responses measured over the same time period as the tests;
the line is an exponential fit to the data obtained in the presence of sildenafil,
giving the indicated rate constant.
Activity-dependent Plasticity in Cellular NO-cGMP Signaling
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centration-response curve for NO-induced, cGMP-dependent
phosphorylation of VASP in rat platelets is biphasic, with NO
concentrations higher than 3 nM giving progressively less VASP
phosphorylation (13). Exposure to a range of clamped NO con-
centrations (0.1–30 nM) for 2 min, however, did not lead to a
significant change in phospho-PDE5 levels (Fig. 5C). As con-
trols in the same experiments, NO produced the usual
concentration-dependent increase in cGMP levels (EC50  10
nM; Fig. 5C) and increased VASP phosphorylation, with a max-
imal effect occurring at about 3 nM NO followed by a decline
(inset, Fig. 5C). All these results suggest that the behavior of
PDE5 in the platelets under the conditions of our experiments
is largely uncomplicated by phosphorylation of the enzyme.
A Quantitative Analysis—The data obtained in the present
study, when combined with the current scheme for NO recep-
tor activation (14, 24–26), allow a kinetic model for NO-cGMP
signaling in rat platelets to be formulated (Fig. 6). There are two
main components to themodel; that is, the NO receptor whose
activation generates cGMP, andPDE5,which is activated by the
binding of cGMP to an agonist site andwhich hydrolyzes cGMP
at its catalytic site. Both components are represented as two-
step reactions; binding of the agonist (NO or cGMP) followed
FIGURE 5. PDE5 phosphorylation. A, time-course of the levels of phospho-PDE5 (P-PDE5) assayed by immunoblotting lysates of platelets previously exposed
to a 50 nM NO pulse (F) or to a persistent (clamped) NO concentration of 50 nM without (E) or with () 100M sildenafil. For a positive control, HEK-GC/PDE5
cells were exposed to 100 M S-nitrosoglutathione in the presence of sildenafil (f) (see Ref. 19). Data are the means S.E.; p 0.05 (*) and p 0.01 (**) by
one-way analysis of variance andDunnett’s post-hoc test (n 3); all other results (3–4 independent platelet samples)were not significantly different (p 0.05)
from their corresponding controls (untreated platelets). Representative blots are shown in the inset, and sample cGMP responses of platelets from the same
experiments are shown in B. Ab, antibody. In C the platelets were exposed to a range of clampedNO concentrations for 2min, and the level of phosphorylated
PDE5 was assayed (; n 3); as controls in the same experiments, the phosphorylation of VASP (P-VASP) was checked (example shown in inset together with
a sample P-PDE blot), and the rise in cGMP in response to different NO concentrations wasmeasured after 2-s exposure (f). Clamped NO concentrations in all
cases were achieved using a mixture of spermine-NONOate and CPTIO (50 M).
FIGURE 6.Model of cellular NO-cGMP kinetics comprising the receptor
kinetics leading to cGMP synthesis and desensitization (A) and the
activation of PDE5 by cGMP, leading to cGMP hydrolysis (B). In A the
states of the heme NO binding site corresponding to each of the receptor
states are indicated in the adjacent schematics, the heme group being
represented by a parallelogram. The values of the kinetic parameters in
italics are given in Table 1.
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TABLE 1
Model parameters
Activity-dependent Plasticity in Cellular NO-cGMP Signaling
25636 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 38•SEPTEMBER 18, 2009
 at U
CL Library Services on N
ovem
ber 19, 2013
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
by a conformational change leading to a catalytically active (or
more active) species. In the case of the NO receptor, the basic
model used is a utilitarian version of a detailed enzyme-linked
receptor mechanism that takes into account the likely concen-
trations of GTP and ATP existing in cells (26). Desensitization
was incorporated using a scheme derived from studies of puri-
fiedNO-activatedGC (27). In this scheme receptor activation is
associated with NO binding distally to the heme prosthetic
group and then the proximal coordinating histidine bond
breaks, facilitating a conformational change. Under conditions
of low GTP, a second NO can bind to the now-vacant proximal
heme site.Dissociation of the distalNOresults in anNO-bound
inactive state of the receptor fromwhich NO leaves very slowly
(see Fig. 6 and “Discussion”). Values for the rate constants gov-
erning the transitions to and recovery from the desensitized
state were based on the experimental data (see Table 1). For
PDE5, it is assumed that all three species (unbound and the two
cGMP-bound states) are able to hydrolyze cGMP in ways that
can be adequately described using Michaelis-Menten kinetics,
as has been found experimentally in rat platelets and other cells
(11, 13). The rate constants describ-
ing PDE5 activation and deactiva-
tion are all constrained by experi-
mental data (Table 1).
A stringent test of any model of
this type is to describe the complete
time-course of cGMP changes in
platelets in response to a range of
NO concentrations because this
entails widely differing rates of
cGMP formation, levels of cGMP,
and PDE activity, all of them chang-
ing with time. The model replicates
well the transient cGMP responses
to NO pulses covering a very wide
range of peak amplitudes, namely
1.7–500nM, in rat platelets (Fig. 7A).
In addition to the responses to NO
pulses, the cGMP transients
observed on exposure to a range of
clamped NO concentrations (13)
are similarly replicated (not illus-
trated). Important in reproducing
the data faithfully are a low resting
PDE5 activity and a relatively slow
rate of activation by the binding of
cGMP to the agonist site, allowing
cGMP to build up for a couple of
seconds before hydrolysis becomes
overwhelming, as is illustrated in
the example of a 17 nM NO pulse
(Fig. 7B). The alternative of having
fast binding to the PDE and a slow
transition to the active state (while
maintaining recovery at its ob-
served rate) fails to fit the data in
Fig. 7A. Desensitization can be
seen most obviously with the
higher NO pulses (170 and 500 nM peaks) where cGMP at the
5-s time point becomes progressively lower than after a
smaller (50 nM) pulse.
On applying the model to the present results, it was found to
describe accurately the progressive desensitization observed on
giving repeated 50 nMNOpulses (Fig. 1A) and reproduces quite
well the progressive cellular tachyphylaxis taking place when
PDE5 is active (assay minus sildenafil), although the experi-
mental data indicated a slightly greater PDE5 activity toward
the end of the train of pulses (Fig. 1A). The changes in the
proportions of unliganded, active, and desensitized receptor
predicted by themodel for this experiment are illustrated in Fig.
1B. Themodel also provides a reasonable fit to the NO concen-
tration-response curves for receptor activation and desensiti-
zation (Fig. 2B) and gives a good depiction of the time-courses
of the depression and recovery from single NO pulses of differ-
ent amplitude assayed bothwith andwithout sildenafil (Fig. 3,C
and D).
Tachyphylaxis during Long Exposure to NO—One prediction
of the model is that NO concentrations much lower than those
FIGURE 7.Model simulation of the acute cGMP responses of rat platelets to a range of NO pulse ampli-
tudes (A andB) and of the behavior of rat cerebellar cells (C andD). The data inA are taken fromour recent
study (14); the model (Fig. 6 and Table 1) had GCmax 105 M/s, Vp2 90 M/s, and k3 0.4 10
7
M
1s1.
Extracellular/boundcGMP (seenas theplateau at 10–20 s)was assumed tobe formedexponentiallywith a rate
constant of 0.5 s1. Theprofiles of a sampleNOpulse (peaking at 17 nM) and the resultingGCandPDE activities
predicted by themodel are illustrated togetherwith the consequent cGMPprofile, in B. The data in C andD are
from the same study asA.C, time-course of cGMP levels in a cerebellar cell suspension after 2NOpulses (100nM
peak amplitude) given 3 min apart (simulated at the top), the second one in the presence of inhibitors of the
operative PDEs (PDE5 and PDE4), namely sildenafil (100 M) and rolipram (1 M). Broken lines are model pre-
dictions using the parameters: GCmax  88 M/s, Vp2  0.8 M/s, and k3  0.7  10
7
M
1s1. The PDE4
parameters additionally incorporatedwere: Vmax 9.5M/s, Km for cGMP 3mM, and KI for rolipram 30 nM.
D, concentration-response curve after 5-s exposures to a range of amplitudes of NO pulses. The broken line is
the model simulation assuming GCmax  77 M/s and the other parameters as in C. For further details, see
Ref. 14.
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evoking acute desensitization (EC50 20 nM, Fig. 2B) or PDE5
activation (EC50  2 nM, Fig. 3A) would be effective if present
tonically, because the two corresponding states would build up
over time. To test this prediction, enduring (20 min) exposures
to fixed NO concentrations in the subnanomolar range were
made using a combination of the slow NO releaser, diethylene-
triamine NONOate (half-life  20 h), and CPTIO (20). As
usual, changes in GC and PDE activities were assayed using 2-s
exposures to a test NO pulse (50 nM peak) in the presence or
absence of sildenafil. With a tonic 10 or 60 pM NO, no signifi-
cant receptor desensitization or PDE activation was detected,
whereas at 200 pM NO there was a significant reduction in the
cGMP response in the absence of sildenafil (Fig. 8A), signifying
enhanced PDE5 activity. An NO concentration of 600 pM gave
an 50% loss of cellular responsiveness which was associated
also with a significant fall in GC activity. The concentration-
response relationships resemble those predicted by the model
(dashed lines, Fig. 8A).
DISCUSSION
Knowledge of the kinetics of cellular NO-cGMP signaling is
needed to understand the behavior of complex tissues in nor-
mal and disease states. Despite much evidence that the NO-
cGMP pathway is subject to acute, activity-dependent regula-
tion, the underlying mechanisms have not been clear. In
general, those authors focusing on NO-activated GC have
attributed the tachyphylaxis to that component while ignoring
possible changes in PDE activity and vice versa (see the Intro-
duction). Using rat platelets as a preparation that yields the
quantitative data needed to address the problem, we find that
changes in activity of both PDE5 and the NO receptor contrib-
ute, but in distinct ways; acutely, PDE5 activation has the lower
threshold (in terms of NO concentration) but only a short term
influence once NO is removed, whereas NO receptor desensi-
tization requires higher NO concentrations but is much more
enduring.
Considering first the role of PDE5, the results showed that
activation of cGMP hydrolysis can have profound conse-
quences in that it can effectively abolish subsequent NO-in-
duced cGMP accumulation, although recovery starts as soon as
the NO disappears. In addition, the phenomenon occurs at low
NO concentrations, a brief pulse peaking at 2 nM NO being
enough to engender a 50% loss of the cGMP response. No data
on the NO concentration dependence of PDE5 activation in
cells were previously available, although the results are compat-
ible with the low nM potency of sodium nitroprusside for acti-
vating PDE5 in gastric smooth muscle cells in vitro during a
1-min exposure, although here the PDE activity was measured
after cell lysis (28).
No previous attempt to measure the duration of the
enhanced PDE5 activity in cells has beenmade either, although
this has been addressed by measuring PDE activity in lysates of
humanplatelets previously treated in vitro for 5minwith a 1M
concentration of the NO donor diethylamine NONOate (half-
life 2.1min; expected [NO],1M) and then incubated with
the NO scavenger CPTIO (15). It was found that the lysate PDE
activity, although maximal immediately after the NO stimula-
tion, remained elevated for more than an hour and that the
elevated activity correlated with cGMP-dependent phospho-
rylation of PDE5, which in cell-free conditions at least, stabi-
lizes the activated state (19). It appears that substantial long
term activation requires higher NO concentrations and/or
more prolonged exposure than used in the present experi-
ments. We usually restricted the NO pulse height to 50 nM
because this is near the top of the NO-cGMP concentration-
response curve. In addition, application of higher concentra-
tions creates problems of secondary sources of NO being cre-
ated in the incubation medium, leading to inadvertent longer
term stimulation (14). Even after this near-maximal condition-
ing pulse, there was no discernible long-term component to
PDE5 activation. Accordingly, on examining the amount of
phosphorylated PDE5 under several relevant conditions, no
change could be detected, although a small increase was
observable when the platelets were exposed to 50 nM NO for 2
min in the presence of sildenafil, a condition leading to high,
sustained cGMP levels. Hence, the measured kinetics of PDE5
FIGURE 8. Effects of tonic NO exposure in rat platelets. Data in A show
cGMP responses after 2-s applications of a 50 nM NO pulse with and without
sildenafil (100M)measured after 20min of incubation in a range of clamped
NO concentrations in the subnanomolar range. p 0.05 (*), p 0.01 (**), and
p  0.001 (***) compared with control (untreated) platelets (t test). Broken
lines are model predictions with GCmax 127 M/s, Vp2 90 M/s, and k3
1 107 M1s1. The dash-dot line assumes an additional more stable active
PDE5 state (see the legend to Fig. 1A). The clamped NO concentrations were
achieved using amixture of diethylenetriamine NONOate and CPTIO (50M).
In B the lines are the cGMP concentrations predicted by themodel (Fig. 6 and
Table 1) to exist inplatelets subjected to variousNOconcentrations for 0.5–15
min (indicated for each curve; the 0.5 min line is dashed for clarity); data rep-
resent the levels of VASP phosphorylation (arbitrary units) measured in rat
platelets after 1 min of exposure to different NO concentrations (13).
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appear largely uncomplicated by alterations in PDE5 phospho-
rylation and are likely, therefore, to reflect the rates of cGMP
binding and unbinding at the agonist site on PDE5.
This does not necessarily imply that a faster rate of deactiva-
tion of PDE5 signifies a lack of phosphorylation. An investiga-
tion using rat cultured smooth muscle cells in vitro found that
atrial natriuretic factor-induced cGMP accumulation resulted
in PDE5 phosphorylation within a minute, but then it declined
to undetectable levels after 3 min, an interval that also corre-
sponded to a 50% loss of the activated state of PDE5 measured
after lysis (29). Obviously, dephosphorylation and the associ-
ated deactivation of PDE5may occur at different rates in differ-
ent cells, providing a mechanism for variably delaying the
return of cellular PDE5 activity to normal beyond the 2-min
period operating under the conditions of our experiments.
Indeed, it cannot be excluded that there is a small component of
more persistent PDE5 activation in the experiments involving
repeated application of 50 nMNO pulses (Fig. 1A) or prolonged
(20-min) exposure to subnanomolar NO concentrations (Fig.
8A) because a rather better fit to these experimental results was
achieved by assuming that the activated PDE5 can undergo a
slow transition to a more stable active species (dotted lines in
Figs. 1A and 8A; see Fig. 1A legend for rate constants). Only
about 10% of the enzyme is required to be in this more stable
active state to provide the fits to the data; if caused by phospho-
rylation, such a change would be very difficult to detect by
Western blotting, and so our results with this technique cannot
exclude it. The predominantly rapid recovery of PDE5 activity
observed in rat plateletsmay applymore generally; for example,
many physiological studies have shown that nitrergic nerve-medi-
ated smoothmuscle relaxations, including of humanmaterial, can
be repeated at regular short intervals (1–5 min) without demon-
strable tachyphylaxis (see the references in Ref. 30).
Turning toNOreceptor desensitization, the acute potency of
NO for inducing desensitization recorded using pulse applica-
tions (Fig. 2B) is very similar to that foundwhen rat platelets are
exposed to clamped NO concentrations, where 10 nM NO gen-
erated progressive desensitization and 3 nM did not, during
exposures lasting up to 1.5 min (13). Despite the relatively high
threshold for inducing desensitization compared with PDE5
activation during short exposures, the phenomenon contrib-
utes to the shaping of the acute cGMP response in rat platelets
toNOat the higher concentrations (13, 14), as illustrated in Fig.
7A. Moreover, in cerebellar astrocytes, which have very low
PDE activity, desensitization is the primarymechanismgovern-
ing the shape of the cGMP response over time (11). A feature
revealed in the present experiments is themuchmore enduring
influence of desensitization compared with PDE5 activation
onceNO is removed, permitting summation of the process over
long time intervals. Hence, an NO concentration more than
10-fold lower than that found to be effective acutely in this and
the previous study (13) could induce significant desensitization
with a 20-min exposure. From its properties, desensitization is
likely to serve as a gain control, titrating cellular sensitivity to
NO according to the past history of NO exposure.
Tonic levels of NO are found in the cardiovascular system
and brain as a result of endothelial NO synthase activity (31–
34). Moreover, the enhanced relaxant potency of NO on blood
vessels in vivo and in vitro shortly after inhibiting NO synthase
or removing the endothelium (18) shows that the smoothmus-
cle normally exists in a state of subsensitivity toNOas a result of
prior exposure to NO. From our findings, the subsensitivity
would be mainly the result of receptor desensitization, as an
enhanced PDE5 activity wouldmostly revert to normal quickly.
In agreement, the supersensitivity observed after endogenous
NO is eliminated does not immediately subside after re-expo-
sure to NO (18), contrary to expectations were the deactivation
of PDE5 chiefly responsible for the supersensitive state. Under
more pathological conditions, desensitization may contribute
to the early loss of NO-stimulated GC activity observed when
the inducible NO synthase, which synthesizes NO continu-
ously, is expressed (35). It may also underlie the reduced NO-
evokedGC activity found in blood vessels when endothelial NO
synthase is overexpressed (36), and its absence could explain
the increased NO-stimulated GC activity observed in mice
lacking endothelial NO synthase (9, 10), as in both cases no
changes in the level of NO receptor protein were found.
Previous analyses of the cGMP profiles of cerebellar astro-
cytes, striatal neurons, and rat platelets exposed to NO (11, 13,
37) gave optimism that it would be feasible to understand quan-
titatively the complex interplay between NO receptor activa-
tion, desensitization, and cGMP hydrolysis in cells. The earlier
attempts using rat platelets (13, 14) were hampered by a lack of
direct information about the kinetics of PDE5 that the data
from the present experiments partially rectifies, enabling an
explicit mechanism to be proposed (Fig. 6) that provides a good
simulation of most of the data from this and previous studies.
For the PDE5 component, an important feature required to
match the data was a slow rate of activation by cGMP, allowing
cGMP to accumulate before being destroyed. Despite being an
empirical value, the low bimolecular rate constant deduced for
cGMP binding (1.7 104 M1s1) transpires to be very similar
to the measured association rate constant for cGMP binding to
the non-catalytic site on the rod photoreceptor PDE (PDE6), a
close relative of PDE5 (38). Another feature of note is the
potency of cGMP for PDE5 activation. In the model (Fig. 6 and
Table 1), the binding affinity is about 8M, and the EC50 is close
to 2 M. Various estimates of the EC50 in cell-free conditions
have been made, but the results have been variable, ranging
from about 1 M (39) to about 50 M (Fig. 7B of Ref.19) with in
both cases a small reductionwhen the enzymewas phosphoryl-
ated by cGMP-dependent protein kinase. The inherent com-
plexity of this approach (cGMP being both an agonist and a
substrate) has been circumvented by measuring stimulation of
the binding of competitive inhibitors acting at the PDE5 cata-
lytic site, which indicated amaximal effect at 25M cGMP (40),
and by studying a chimeric protein with an adenylyl cyclase
substituted for the catalytic domain (41), where the cGMPEC50
came to 10 M, reducing to 2 M when phosphorylation was
mimicked by mutation. In all, our empirical estimate of the
potency of cGMP in the intact cell is compatible with those
measured under cell-free conditions.
To incorporate desensitization into the model, we initially
examined classical mechanisms in which the desensitized state
is reached reversibly from one or more agonist-bound states
(42, 43). Although adequate for describing changes occurring
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over the first few seconds of NO exposure (14), such mecha-
nisms failed the more stringent tests reported here. In particu-
lar, the classical models predict that, with such a slow rate of
recovery from desensitization (Fig. 4), the receptor must even-
tually become almost totally desensitized after repeated or pro-
longed NO exposure, whereas in the present experiments and
those reported previously (13), desensitization stabilized max-
imally at about 80%. A satisfactory solution was achieved by
formalizing a scheme proposed from studies on purified NO-
activated GC (27) in which NO exposure in the absence of sub-
strate leads to the formation of a stable inactive receptor with
NO bound on the “wrong” side of the heme. The existence of
such a species is consistent with crystallographic evidence from
a related bacterial cytochrome (44) and with the finding that
GC activity could be restored by adding excess NO in the pres-
ence of a high substrate concentration (27). In agreement with
this mechanism subserving desensitization in cells, the rate of
recovery of platelet GC activity from desensitization that we
measured (k  7.34  104 s1) is remarkably similar to the
rate of dissociation of NO from the NO-bound inactive GC
species (produced by exposure to NO in the absence of GTP)
for which rate constants of 7 104 s1 at 20 °C (45) and 3
104 s1 at 10 °C (46) have been reported.
Although direct evidence would be hard to find, it is reason-
able to suppose that there is a transient depletion of GTP in the
vicinity of activeGC, bearing inmind that the total cellularGTP
concentration is about 100 M (47–50) and that, when maxi-
mally stimulated by NO, cellular GC in platelets consumes
about 70 M GTP/s. The transient dip in GC activity seen dur-
ing exposure to a 50 nM NO pulse before the appearance of
steady desensitization (Fig. 2A) plausibly reflects a reduction in
GTP concentration followed by recovery.
It should be mentioned that the inactive NO-bound species
referred to above has been considered by one group to display a
low (10–20% ofmaximum) intrinsic activity (46). That the spe-
cies in question acts as an NO donor (half-life15min), which
on releasing its NO becomes an active GC again (as in the
model, Fig. 6), would explain the observed activity. In addition,
the experimentsmay have been compromised by the formation
of secondary NO donors in the buffer that could artifactually
add to the activity (14).
Without direct evidence, the proposed desensitization
scheme must be regarded as tentative; nevertheless, it has the
merits of replicating experimental results on platelets in detail
and of making correct predictions regarding the effect of long
term NO exposure (Fig. 8A) as well as being concordant with
data from purified NO-activated GC. Other proposed mecha-
nisms of desensitization have included oxidation and loss of the
NO binding heme, which was found not to contribute measur-
ably to desensitization in rat platelets (22), thiol nitrosation
(51), and cGMP-dependent phosphorylation (52, 53). Thiol
nitrosation is unlikely to have intruded on our experiments
because it has been observed only under extreme conditions,
for example after 1 h of exposure to 0.1–1mM S-nitrosocysteine
(53). A study in cerebellar astrocytes foundno effect of kinase or
phosphatase inhibitors on desensitization occurring during a
2-min exposure to NO (37), implying that changes in phospho-
rylation were not instrumental. The phosphorylation mecha-
nism appears to require longer exposures to NO, and it also
seems unable to give the required degree (80%) of desensitiza-
tion (51). Its participation in the lesser effect found after long
(20-min) exposure to subnanomolar NO concentrations (Fig.
8A), however, is not excluded.
To scrutinize the generalizability of our model, we analyzed
results from cerebellar astrocytes (14), a cell type having a very
low cGMP-hydrolyzing PDE activity comprising a mixture of
PDE5 and PDE4 (54). The effects of twin 100 nM NO pulses
given 3min apart are accurately simulated, including the degree
of desensitization (50%) evident on applying the second pulse
(Fig. 7C). Also well simulated is the bell-shaped NO concentra-
tion-response curve found in astrocytes with 5-s applications of
NO pulses of differing amplitude (Fig. 7D), the biphasic shape
of the curve being caused by desensitization (55). Hence, the
kinetics of desensitization deduced using platelets appears to
apply to other cells.
Having a quantitativemodel helps in interpreting results and
inmaking predictions. To take just one example relevant to the
present study, cGMP-dependent phosphorylation of VASP in
rat platelets shows a puzzling biphasic relationship to NO con-
centration (delivered in the clamped mode) in that low NO
concentrations (EC50  0.5 nM) give more phosphorylation
than higher ones (3 nM) even though the higher ones give
more cGMP (Fig. 5C andRef. 13). The intuitive interpretation is
that higher NO concentrations inhibit phosphorylation inde-
pendently of cGMP (13). However, cGMP was measured dur-
ing its transient increase (lasting about 10 s), whereas phos-
phorylation was assessed after an exposure of 1 min (2 min in
Fig. 5C). With the model, we can analyze what happens to
cGMP levels beyond the transient peak. The result (Fig. 8B)
would not have been foreseen. It shows a strongly biphasic rela-
tionship between NO concentration and cGMP accumulation
after 0.5–1 min of exposure, arising from the non-linearities
between GC activity, cGMP concentration, and PDE activity
over time. The EC50 forNOnowbecomes about 1 nM instead of
10 nM initially and, even if too small to measure directly, cGMP
still is present at the submicromolar concentrations active on
cGMP-dependent protein kinase (56). NO concentrations of
5–25 nM give progressively less cGMP. With exposures longer
than 1 min, the curve gradually resolves to a conventional sig-
moidal type (EC50 0.9 nM after 15min; Fig. 8B). The shapes of
the curves with 0.5–1 min exposures to NO, therefore, provide
a good match to the biphasic shape of the concentration-re-
sponse curve forVASPphosphorylationmeasuredwith a 1-min
exposure (Fig. 8B).Withmore sustainedNOapplication, there-
fore, it is probably the persisting low cGMP level that primarily
determines the extent of downstream phosphorylation rather
than the size of the initial cGMP surge. This interpretation is
consistent with data showing that VASP phosphorylation con-
tinues to increase after the surge is over (13).
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